U.S. markets closed
  • S&P Futures

    4,222.00
    +12.00 (+0.29%)
     
  • Dow Futures

    33,360.00
    +100.00 (+0.30%)
     
  • Nasdaq Futures

    13,447.00
    +55.00 (+0.41%)
     
  • Russell 2000 Futures

    1,975.70
    +6.20 (+0.31%)
     
  • Crude Oil

    91.83
    -0.10 (-0.11%)
     
  • Gold

    1,801.60
    -12.10 (-0.67%)
     
  • Silver

    20.47
    -0.28 (-1.34%)
     
  • EUR/USD

    1.0286
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2184
    -0.0034 (-0.28%)
     
  • USD/JPY

    133.2900
    +0.4170 (+0.31%)
     
  • BTC-USD

    24,323.83
    +1,478.24 (+6.47%)
     
  • CMC Crypto 200

    573.44
    +42.22 (+7.95%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research.

  • 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients.

  • The Company's PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

  • The PHP system is being developed under the tradename, Hepzato Kit.

  • Related: Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial.

  • The analysis demonstrated a hepatic disease control rate of 88.9% (72/81), a hepatic response rate of 66.7%, and an overall response rate of 60.5%.

  • After a median follow-up of 12.9 months, median overall progression-free survival (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively.

  • Treatment-emergent adverse events of Grade 3 or 4 occurred in 23 patients, anemia observed in 11 patients (13.3%), and thrombocytopenia in 10 patients (12%).

  • There were no fatal treatment-related adverse events.

  • Price Action: DCTH shares closed at $6.99 on Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.